Cost of epilepsy in the United States: a model based on incidence and prognosis.
about
Bridging the Gap between Evidence and Practice for Adults with Medically Refractory Temporal Lobe Epilepsy: Is a Change in Funding Policy Needed to Stimulate a Shift in Practice?Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as ExamplesThe direct cost of epilepsy in the United States: A systematic review of estimatesSurgical versus medical treatment for refractory epilepsy: outcomes beyond seizure controlUse of anterior temporal lobectomy for epilepsy in a community-based population.Closed-loop neural stimulation for pentylenetetrazole-induced seizures in zebrafish.Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamidesAntiepileptic drug treatment: outcomes and adherence.Strategies for optimizing antiepileptic drug therapy in elderly people.New anti-epileptic drugs for the 21st century.Estimating the costs of epilepsy: an international comparison of epilepsy cost studies.Economic evaluation of antiepileptic drug therapy: a methodologic review.The economic cost of epilepsy: a review of the literature.A comparison of surgical and medical costs for refractory epilepsy.Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended releaseNeurologists' knowledge of and attitudes toward epilepsy surgery: a national surveySurveying the population with epilepsy: ulcers, allergies, and other medical comorbidities.Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders.Childhood febrile seizures: overview and implicationsHealth resource use in epilepsy: Significant disparities by age, gender, and aboriginal status.Economic aspects of epilepsy and antiepileptic treatment: a review of the literature.Mapping the temporal pole with a specialized electrode array: technique and preliminary resultsThe use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications?Ketogenic Diet Decreases Emergency Room Visits and Hospitalizations Related to Epilepsy.The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Topiramate: a new antiepileptic drug.Algorithm on the clinical evaluation of epilepsy.Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy.Intracranial electroencephalography with subdural grid electrodes: techniques, complications, and outcomes.Health Care Utilization Following Vagus Nerve Stimulation Therapy in Pediatric Epilepsy Patients From a Pediatric Accountable Care Organization.Epilepsy: a costly misdiagnosis.The costs of childhood epilepsy in Italy: comparative findings from three health care settings.Economic burden of epilepsy in India.Gesundheitsökonomie und Lebensqualität bei EpilepsieDirekte und indirekte Kosten der Epilepsie
P2860
Q26771796-3CB82F73-57C2-4FA4-AE0C-0B7B734E9466Q26774170-5A555E52-610C-4FFD-9E08-11B1D29C314CQ26799129-C5A5C727-9D55-4062-AFC6-B1C1E03DF41AQ26996548-AC5A3BA5-F54E-4245-BFA1-B8236D073AAEQ30447645-A1C33334-CDA6-496D-A80C-C98F2F05C4A0Q30530608-3A095C65-6DC0-4B7D-B6D5-0EB82376E2F3Q33640451-F3F36204-43EA-4743-A945-55BF2B3A1FB3Q33999491-1D2747C9-A806-4F5E-80E6-D6F7108B28A0Q34118987-EF21B892-ED97-4552-88EC-C915F13559A2Q34182061-F347DD86-DD7E-432D-AB92-BAB55C4F2E00Q34266360-44F28B95-68EE-43DA-8A0C-034B6A13307EQ34655336-0554FD85-6BF0-4A88-AEAF-BDF98F7509C9Q34680646-32933D9F-C5E9-46A4-A5DC-957401BBA337Q34680659-DBF05EFF-9AFD-435C-808C-CF6EE04826F3Q34942400-48913940-17AA-4463-9508-34942E79CF93Q35106515-A3AA4F09-E11C-4D3D-9E71-F1BF2A1F5D51Q35612532-11CA9C71-429E-44FF-BFF7-5E9B9C46A8A4Q36673011-928BC6D2-C858-433D-BD9C-132F4DA0BDB0Q36811150-69A25F9E-261C-44ED-BFC7-939548A994E0Q37051386-B474B294-8A54-4F39-868D-5CFCE5696306Q37609418-FBB0B23B-1110-4B69-990B-3D737704BBD0Q37711885-A4784F39-9B28-4A35-B8A5-E0562CD90EC3Q37957129-3425615C-7D6A-48E8-81A7-6A10D201CEE5Q38983456-3138DB9B-12D4-4311-882F-0F3E151F77E1Q38985697-26D66E54-B070-49BC-89F5-04C6AF233CE1Q41616230-D67D3B16-ABC6-4160-8647-BEE2E55A30FCQ41621057-7635AE8A-BF32-4E55-BE0E-EBADCAEA2D17Q43266403-BB61A8EF-B842-4170-A32F-0AFBC846284BQ45173518-1BAE81F8-F8F8-4CD1-888E-5F2D46976DDEQ47417876-24634189-2FB9-44A4-8D04-F2D833B867BDQ50625789-4866AFAB-C4A7-4AF6-BD9E-050CAD4F1E6AQ50675442-770DF153-7642-4425-B7DA-3448DB04E82EQ50682892-FF3BB3A9-1E0C-4058-B242-9B9481A390C2Q58594852-809A8080-FC54-4271-91D2-7321D205A4A1Q58595140-EFF4F56B-E013-412C-B45E-2E37EE3835BF
P2860
Cost of epilepsy in the United States: a model based on incidence and prognosis.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@en
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@nl
type
label
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@en
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@nl
prefLabel
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@en
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@nl
P2093
P1433
P1476
Cost of epilepsy in the United States: a model based on incidence and prognosis.
@en
P2093
Annegers JF
Lairson DR
Reynolds TF
P304
P356
10.1111/J.1528-1157.1994.TB01794.X
P577
1994-11-01T00:00:00Z